Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC)

被引：1
|
作者：
Zelek, L. [1 ]
Debourdeau, P. [2 ]
Bourgeois, H. [3 ]
Wagner, J. P. [4 ]
Brocard, F. [5 ]
Lefeuvre-Plesse, C. [6 ]
Chauffert, B. [7 ]
Leheurteur, M. [8 ]
Bachet, J-B. [9 ]
Simon, H. [10 ]
Mayeur, D. [11 ]
Jovenin, N. [12 ]
Scotte, F. [13 ]
机构：
[1] Hop Avicenne, AP HP, Med Oncol, Bobigny, France
[2] Inst St Catherine, Oncol Support Care, Avignon, France
[3] Clin Victor Hugo, Med Oncol, Le Mans, France
[4] Inst Andree Dutreix & Clin Flandre, Res Innovat & External Commun, Dunkerque, France
[5] Polyclin Gentilly, Med Oncol, Nancy, France
[6] Ctr Eugene Marquis, Med Oncol, Rennes, France
[7] CHU Amiens Picardie Site Nord, Med Oncol Dept, Amiens, France
[8] Ctr Henri Becquerel, Med Oncol, Rouen, France
[9] Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, Paris, France
[10] CHU Morvan, Inst Cancerol & Hematol, Brest, France
[11] Ctr George Francois Leclerc, Med Oncol, Dijon, France
[12] Inst Canc Courlancy Reims, Med Oncol, Reims, France
[13] Gustave Roussy, Interdisciplinary Canc Course Dept, Canc Ctr, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1672P
引用
收藏
页码：S1175 / S1175
页数：1
相关论文
共 50 条
  • [21] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [22] Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
    Zhang, Li
    Lu, Shun
    Feng, Ji Feng
    Dechaphunkul, Arunee
    Chessari, Salvatore
    Lanzarotti, Corinna
    Jordan, Karin
    Aapro, Matti S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
    Molasiotis, A.
    Aapro, M. S.
    Alonzi, A.
    Chrapava, M.
    Jordan, K.
    Roeland, E. J.
    Schwartzberg, L. S.
    Terrasanta, C.
    Olivari, S.
    Dranitsaris, G.
    ANNALS OF ONCOLOGY, 2022, 33 : 1546 - 1546
  • [24] Assessing the Benefit of NEPA (Fixed Combination of Netupitant/Palonosetron) for preventing Chemotherapy-induced Nausea and Vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
    Karthaus, M.
    Christoph, D. C.
    Lux, M. P.
    Hofheinz, R. -D
    Jordan, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 252 - 253
  • [25] Quality of life (QOL) evaluation of patients in a phase 3 study comparing NEPA with an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV)
    Zhang, L.
    Lu, S.
    Feng, J.
    Dechaphunkul, A.
    Chessari, S.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] ANALYSIS OF PALONOSETRON VS ONDANSETRON IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PEDIATRIC PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)
    Kovacs, G.
    Wachtel, A. E.
    Basharova, E. V.
    Spinelli, T.
    Nicolas, P.
    Kabickova, E.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S108 - S108
  • [27] Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    Warr, DG
    Hesketh, PJ
    Gralla, RJ
    Muss, HB
    Herrstedt, J
    Eisenberg, PD
    Raftopoulos, H
    Grunberg, SM
    Gabriel, M
    Rodgers, A
    Bohidar, N
    Klinger, G
    Hustad, CM
    Horgan, KJ
    Skobieranda, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2822 - 2830
  • [28] 3-day Aprepitant Plus Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving Cisplatin-based Chemotherapy
    Sym, S. J.
    Hong, J.
    Jung, M.
    Park, J.
    Cho, E. K.
    Lee, J. H.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S245 - S245
  • [29] Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
    Gao, Ai
    Guan, Shasha
    Sun, Yinjuan
    Wang, Lingling
    Meng, Fanlu
    Liu, Xia
    Gu, Liyan
    Li, Guo
    Zhong, Diansheng
    Zhang, Linlin
    BMC CANCER, 2023, 23 (01)
  • [30] Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
    Ai Gao
    Shasha Guan
    Yinjuan Sun
    Lingling Wang
    Fanlu Meng
    Xia Liu
    Liyan Gu
    Guo Li
    Diansheng Zhong
    Linlin Zhang
    BMC Cancer, 23
12345